Successful treatment of gamma 1 heavy chain deposition disease with bortezomib and dexamethasone

Successful treatment of gamma 1 heavy chain deposition disease with bortezomib and dexamethasone

Heavy chain deposition disease (HCDD) is a rare complication of plasma cell dyscrasias, characterized by nonamyloid tissue deposits of incomplete monoclonal heavy chains in renal tissues. We report the case of a 78-year-old female with HCDD who was successfully treated with bortezomib and dexamethas...

Full description

Bibliographic Details
Main Authors:	Masanori Sudo, Takuya Wakamatsu, Tomomi Ishikawa, Masato Habuka, Michihiro Hosojima, Suguru Yamamoto, Yumi Ito, Naofumi Imai, Yoshikatsu Kaneko, Akira Shimizu, Ichiei Narita
Format:	Article
Language:	English
Published:	Elsevier 2019-03-01
Series:	Human Pathology: Case Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2214330018301263

Similar Items

Cryofibrinogen-associated glomerulonephritis diagnosed by mass spectrometry and immunoelectron microscopy
by: Masanori Sudo, et al.
Published: (2019-03-01)

Comparison of bortezomib-cyclophosphamide-dexamethasone <em>versus</em> bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients
by: Rafiye Ciftciler, et al.
Published: (2020-05-01)

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
by: N. O’Connor-Byrne, et al.
Published: (2019-02-01)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
by: Mir Sadaqat Hassan Zafar, et al.
Published: (2018-01-01)

Increased Proinflammatory Cytokine Production and Decreased Cholesterol Efflux Due to Downregulation of ABCG1 in Macrophages Exposed to Indoxyl Sulfate
by: Koji Matsuo, et al.
Published: (2015-08-01)

Comparison of cyclophosphamide–thalidomide–dexamethasone to bortezomib–cyclophosphamide–dexamethasone as induction therapy for multiple myeloma patients in Brazil
by: Suelen Vigolo, et al.
Published: (2017-09-01)

Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide/Bortezomib/Ascorbic Acid/Dexamethasone (ABCD) Regimen Compared to Bortezomib/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients
by: Qian W, et al.
Published: (2020-01-01)

Indoxyl Sulfate Promotes Macrophage IL-1β Production by Activating Aryl Hydrocarbon Receptor/NF-κ/MAPK Cascades, but the NLRP3 inflammasome Was Not Activated
by: Takuya Wakamatsu, et al.
Published: (2018-03-01)

Treatment of scleromyxedema with lenalidomide, bortezomib and dexamethasone: A case report and review of the literature
by: Hninyee Win, et al.
Published: (2020-12-01)

A rare case of MGRS with immunotactoid glomerulopathy responding to bortezomib, dexamethasone, and rituximab
by: Chaoyuan Kuang, et al.
Published: (2020-10-01)

Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma
by: Claudio Cerchione, et al.
Published: (2016-01-01)

Treatment of idiopathic light chain deposition disease: complete remission with bortezomib and dexamethasone
by: João Tadeu Damian Souto Filho, et al.

Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
by: Maria V. Mateos, et al.
Published: (2021-04-01)

Cost-effectiveness of lenalidomide in combination with dexamethasone compared to bortezomib in combination with dexamethasone for the second-line treatment of multiple myeloma in Chile
by: Susana Aceituno, et al.
Published: (2018-06-01)

Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma.
by: Takashi Yoshida, et al.
Published: (2018-01-01)

Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
by: Kristian T. Andersen, et al.
Published: (2020-01-01)

Lambda Light Chain Myeloma with Oliguric Cast Nephropathy and Remission with Bortezomib, Doxorubicin and Dexamethasone
by: R Hada, et al.
Published: (2012-12-01)

Lambda Light Chain Myeloma with Oliguric Cast Nephropathy and Remission with Bortezomib, Doxorubicin and Dexamethasone
by: R Hada, et al.
Published: (2012-12-01)

Case Report on Renal Failure Reversal in Lambda Chain Multiple Myeloma with Bortezomib and Dexamethasone
by: Bhanu K. Patibandla, et al.
Published: (2014-01-01)

Fatal Cytomegalovirus Pneumonia and Associated Herpes Virus Infection in a Relapsed/Refractory Multiple Myeloma Patient Treated with Bortezomib plus Dexamethasone
by: Daisuke Taniguchi, et al.
Published: (2009-07-01)

Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
by: Edvan De Queiroz Crusoe, et al.
Published: (2020-04-01)

Association of estimated dietary acid load with albuminuria in Japanese adults: a cross-sectional study
by: Keiko Kabasawa, et al.
Published: (2019-05-01)

Fatal visceral disseminated varicella zoster infection during initial remission induction therapy in a patient with lupus nephritis and rheumatoid arthritis—possible association with mycophenolate mofetil and high-dose glucocorticoid therapy: a case report
by: Masato Habuka, et al.
Published: (2018-03-01)

Reduced weekly subcutaneous doses of bortezomib in combination with cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma
by: Farzaneh Ashrafi, et al.
Published: (2020-01-01)

Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients
by: Shenghao Wu, et al.
Published: (2015-01-01)

Treatment of Coexisting Chronic Neutrophilic Leukemia and Light Chain Multiple Myeloma with Hydroxyurea, Bortezomib, and Dexamethasone
by: Evelyn Taiwo, et al.
Published: (2014-01-01)

Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma
by: Michael Dolph, et al.
Published: (2021-08-01)

Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma
by: Michael Dolph, et al.
Published: (2021-08-01)

US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma
by: Dolph M, et al.
Published: (2021-06-01)

Bendamustine-bortezomib-dexamethasone (BVD) in heavily pretreated multiple myeloma: old/new in novel agents’ era
by: C. Cerchione, et al.
Published: (2020-10-01)

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk
by: Katja Weisel, et al.
Published: (2020-08-01)

Bortezomib, Lenalidomide and Dexamethasone as Induction Therapy Prior to Autologous Transplantation in Multiple Myeloma: The More Is Likely the Better
by: Mohamad Mohty, et al.
Published: (2020-05-01)

Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma
by: Taleb Azarm, et al.
Published: (2012-01-01)

Changes in circulating endothelial progenitor cells predict responses of multiple myeloma patients to treatment with bortezomib and dexamethasone
by: L. Wang, et al.
Published: (2015-08-01)

A Case of Multiple Myeloma with Metachronous Chronic Myeloid Leukemia Treated Successfully with Bortezomib, Dexamethasone, and Dasatinib
by: Samer Alsidawi, et al.
Published: (2014-01-01)

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
by: Anderson, L.D., Jr, et al.
Published: (2022)

Efficacy and safety of bortezomib with dexamethasone regimen in elderly newly diagnosed multiple myeloma patients with co-morbidities
by: Lee, Saem
Published: (2016)

Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma
by: Jacob P. Laubach, et al.
Published: (2021-02-01)

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
by: Xiang Zhou, et al.
Published: (2020-08-01)

Bortezomib plus dexamethasone induction followed by autologous stem cell transplantation in multiple myeloma: A study from India
by: Jeevan Kumar
Published: (2016-07-01)